The Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Unanimously Recommended That Enrollment In Cabinet Trial Be Stopped And Randomized Patients Be Unblinded To Therapy With The Allowance For Crossover From Placebo To Cabozantinib Due To The Substantial Improvement In Progression-free Survival (Pfs) Observed At This Interim Analysis.
Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib; Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Recommends Trial Enrollment To Be Stopped
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated